Mirum's Volixibat Achieves Interim Analyses In VANTAGE PBC And VISTAS PSC Studies; Showed 3.8 Point Reduction From Baseline And 2.3 Point Placebo-Adjusted Reduction In Primary Endpoint Of Pruritus
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals announced positive interim results from two Phase 2b studies evaluating volixibat in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The VANTAGE PBC study showed a significant reduction in pruritus and serum bile acids, while the VISTAS PSC study exceeded the efficacy threshold for continuation.
June 17, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals' volixibat demonstrated significant efficacy in reducing pruritus and serum bile acids in PBC patients, and the PSC study exceeded the efficacy threshold for continuation. This positive data could boost investor confidence and potentially drive the stock price up.
The interim results from the VANTAGE and VISTAS studies indicate that volixibat is effective in treating PBC and PSC, which are significant milestones for Mirum Pharmaceuticals. The statistically significant improvements in pruritus and serum bile acids, along with the continuation of the PSC study, are likely to positively impact investor sentiment and the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100